Library · Immune · HIV entry inhibitor for drug-resistant infections
Enfuvirtide
T-20, Fuzeon, DP178, Pentafuside
Synthetic 36-amino-acid peptide from the 1990s, the first HIV fusion inhibitor and first peptide-based antiretroviral, approved by the FDA in 2003. Mimics part of HIV’s gp41 protein to block viral entry into T-cells; used in salvage therapy for treatment-experienced, multi-drug-resistant HIV patients.
Research score 90/100. Reference only, not a dose.
- Anti-viral
- Immune Boosting
- Anti-inflammatory
- Inflammation Resolution
- US status
- FDA Approved
- Approval
- FDA + EMA Approved
- Evidence
- FDA-approved HIV fusion inhibitor (Fuzeon). Used in combination therapy for treatment-experienced patients.
- Research score
- 90 / 100
- Indication
- HIV/AIDS (Entry Inhibitor)
- Origin
- USA
- Source category
- Immune System
- Status group
- Approved / prescription
Mechanism
Binds the HR1 region of HIV’s gp41 envelope protein, preventing the six-helix bundle formation needed for virus-cell membrane fusion, blocking entry before infection; active against both CCR5- and CXCR4-tropic strains.
Safety file
Injection-site reactions are nearly universal (about 98%) and can be painful; increased bacterial pneumonia risk and rare but serious hypersensitivity reactions.
- Injection site reactions
- Local pain and nodules
- Increased risk of bacterial pneumonia
- Hypersensitivity reactions
- Insomnia